hrvatski

Intrathecal chitotriosidase activity as a potential biomarker of disease progression in patients with multiple sclerosis.

Introduction: Multiple sclerosis (MS), as an immune-mediated inflammatory disease, is characterized by the activation of resident macrophages in the central nervous system. Chitotriosidase activity is considered to be a biochemical marker of macrophage activation. The aim of our study was to assess the correlation of intrathecal chitotriosidase activity with the extent of disability symptoms in patients suffering from MS. Subjects and Methods: The study included 170 MS patients classified into two groups according to the severity of neurological disability. Chitotriosidase activity in cerebrospinal fluid and serum samples was determined by measuring the enzymatic hydrolysis product 4-methylumbelliferone fluorimetrically at specified excitation (365 nm) and emission (450 nm) wavelengths. Chitotriosidase ratio (CSF Chit/Serum Chit) was used as the indicator of intrathecal rather than peripheral activity. Statistical analysis was performed using MedCalc and non-parametric Mann-Whitney test was used to assess differences between groups. Results: The median of chitotriosidase activity ratio was 0.10 (95%CI 0.09-0.11) in the group of patients with minimal disability or abnormal neurological signs and 1.18 (95%CI 0.95-1.29) in patients experiencing moderate or severe disability, showing statistically significant difference (P<0.001). Our results show that a higher chitotriosidase activity ratio is associated with disability accumulation. Conclusion: Our study underlines the importance of the innate immune response in the pathogenesis of multiple sclerosis. A significant increase of intrathecal chitotriosidase activity was found in severely disabled patients with limited physical and cognitive functions. Therefore, chitotriosidase activity ratio could be used as a potential biomarker of disease progression in patients with multiple sclerosis. Further investigations with detailed clinical data should be performed in order to establish optimal discrimination criteria.

hitotriozidaza, multipla skleroza

nije evidentirano

engleski

Intrathecal chitotriosidase activity as a potential biomarker of disease progression in patients with multiple sclerosis.

Introduction: Multiple sclerosis (MS), as an immune-mediated inflammatory disease, is characterized by the activation of resident macrophages in the central nervous system. Chitotriosidase activity is considered to be a biochemical marker of macrophage activation. The aim of our study was to assess the correlation of intrathecal chitotriosidase activity with the extent of disability symptoms in patients suffering from MS. Subjects and Methods: The study included 170 MS patients classified into two groups according to the severity of neurological disability. Chitotriosidase activity in cerebrospinal fluid and serum samples was determined by measuring the enzymatic hydrolysis product 4-methylumbelliferone fluorimetrically at specified excitation (365 nm) and emission (450 nm) wavelengths. Chitotriosidase ratio (CSF Chit/Serum Chit) was used as the indicator of intrathecal rather than peripheral activity. Statistical analysis was performed using MedCalc and non-parametric Mann-Whitney test was used to assess differences between groups. Results: The median of chitotriosidase activity ratio was 0.10 (95%CI 0.09-0.11) in the group of patients with minimal disability or abnormal neurological signs and 1.18 (95%CI 0.95-1.29) in patients experiencing moderate or severe disability, showing statistically significant difference (P<0.001). Our results show that a higher chitotriosidase activity ratio is associated with disability accumulation. Conclusion: Our study underlines the importance of the innate immune response in the pathogenesis of multiple sclerosis. A significant increase of intrathecal chitotriosidase activity was found in severely disabled patients with limited physical and cognitive functions. Therefore, chitotriosidase activity ratio could be used as a potential biomarker of disease progression in patients with multiple sclerosis. Further investigations with detailed clinical data should be performed in order to establish optimal discrimination criteria.

chitotriosidase, multiple sclerosis

nije evidentirano